Of note, compared with the Diabetes specialist clinics, use of SGLT2 inhibitors (13.2% versus 43.2%), GLP1-RAs (1.0% versus 6.2%), DPP4 inhibitors (15.4% versus 47.9%), and insulin (27.7% versus 58.1%) were lower in the General medicine clinics (Table 2 and Fig 3). This evidence concerns the gene GLP1R and diabetes mellitus.